The role of photonics and natural curing agents of TGF-β1 in treatment of osteoarthritis by Ahmadi, E.D. et al.
 
 
 
 
 
 
 
 
The Role of Photonics and Natural Curing Agents of TGF-β1 in 
Treatment of Osteoarthritis 
 
Ehsaneh Daghigh Ahmadi, Tehmeena Israr Raja, Seyed Ali Khaghani, 
Chin Fhong Soon, Masoud Mozafari, Mansour Youseffi, Farshid Sefat 
 
 
Abstract 
 
Osteoarthritis (OA) is a degenerative disease leading to the breakdown of the hyaline cartilage between a varieties of 
diarthrodial joints such as the knee joint, carpals of the wrist and etc. When the cartilage is affected by trauma or wear 
and tear, Osteolysis may occur; broken debris of cartilage found within the synovial fluid may be recognised as a 
pathogen and therefore, the body’s autoimmune response will directly target the cartilage for destruction. Cytokines 
are proteins/peptides of glycoproteins that are secreted by cells and are involved in interaction and communication 
between cells. Transforming Growth Factors Beta 1 (TGF-β1) is one of well-known cytokines and had shown many 
effects on cellular biology including simulation or inhibition of cell proliferation, differentiation, production of 
extracellular matrix (ECM), remodelling, and producing both hormones and growth factors. On the other hand, 
Photonics recently play an important role for treatment of OA. The main aim of this review article is to investigate 
the effect of TGF-β1 in treatment of OA. Other important aim of this work is to explore the broad applications of 
optics and photonics in biomedical applications including treatment of OA. Biomedical applications of photonics 
have broad aspects including laser, carbon nanotubes (CNTs), quantum dots (QDs) and graphene and photodynamic 
therapy (PDT) which discussed in this review paper. 
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1. Introduction 
 
1.1. Osteoarthritis 
 
Osteoarthritis (OA) is a progressive degenerative disease, which includes reduction of cartilage thickness between 
two bones in a joint, causing painful bone-to-bone contact. OA affects over 8 million people in the UK alone [1]. 
Overtime, the articular cartilage continues to degrade, reducing shock absorbance, leading to painful bone-to-bone 
contact [2]. When degradation of the cartilage occurs, the water retention properties are reduced due to the breakdown 
of the 3D matrix; as the hyaline cartilage has not access to vital lymphatics other than through diffusion and it also 
lacks blood vessels, healing and repair cannot occur [1]. This conveys that when degradation of the cartilage occurs, 
regeneration is not possible ergo a replacement is needed for one to continue with day-to-day activities. By fabricating 
degradation of articular cartilage under laboratory conditions, one can monitor and manipulate various factors in order 
to fully comprehend how the collagen matrix enables the retention of water and how other factors may influence the 
regrowth of cartilage [2]. Tables 1 and 2 demonstrated below convey both the surgical and non-surgical existing 
treatments for osteoarthritis, emphasizing the need for further study within this field [3]. 
 
 
1.2. The Relevance of TGF-β 
 
TGF-β works by stimulating synthesis of proteoglycans and collagen type II alongside downregulating catabolic 
enzymes, which may degrade cartilage. A catabolic reaction of Interleukin one works by suppressing the synthesis of 
proteoglycans however, research suggests TGF-β plays a role in counteracting this reaction ergo temporarily 
protecting the cartilage from further damage [4-6]. There are two categories of TGF-β including anti-inflammatory 
and pro-inflammatory cytokines based on the circumstances in which they are present [7]. There are currently five 
different known isoforms of TGF-β (1-5). TGF-β1 is known to suppress anabolic cytokine production by inhibiting 
macrophages alongside counteracting interleukin 1, 2 and 6 [3, 8]. 
 
 
 
 
Table 1 – Non-Surgical Treatments of Osteoarthritis [3] 
 
Name of treatment Functionality expansion 
Drug use- Painkillers 
(analgesics) including 
non-steroidal Anti- 
inflammatory drugs 
(NSAID’s) 
- Targets the PNS in order to prevent pain signals being conducted to the brain. 
- Targets the CNS to ensure the brain doesn’t recognise the pain signals being conducted. 
- Examples include paracetamol, aspirin and Ibuprofen. 
- Some forms of NSAID’s may prevent GAG synthesis that may further aggravate damaged 
cartilage therefore the treatment may be proved futile [3]. 
 
Drug use- Steroidal Anti- 
inflammatory drugs 
- Uses steroids to target the effected joint, reducing local inflammation. 
- These drugs contain Cortisone, which is known to cause long-term damage to the liver, 
therefore are not the preferred choice of treatment [3]. 
 
Physiotherapy - Uses exercise to increase the mobility of the joint to aid in cartilage repair. 
- May cause an increase of GAG production however cartilage is irreparable therefore this 
cannot be considered a cure 
 
 
 
 
 
Table 2 – Surgical Treatments of Osteoarthritis 
 
Name of treatment Functionality expansion 
Arthroplasty - A form of joint replacement (total or partial) 
- This treatment wastes healthy tissue as when osteoarthritis occurs, only the cartilage 
is damaged; arthroplasty would remove the majority of the joint including healthy 
tissue, hence why is not seen as an appropriate treatment. 
- Pain relief after healing is the only advantage. 
 
 
Figure 1. Example of total knee replacement arthroplasty [9]. 
 
 
 
Arthroscopy - Removal of loose cartilage present in the inflamed synovial capsule via the use of an 
arthroscope and shaver in order to reduce inflammation and increase mobility. 
- May cause other issues such as blood clots, infection, and threat of dislocation as a 
result of a loose joint. 
 
 
Figure 2. Example of total knee replacement arthroplasty [9]. 
 
 
 
Osteochondral grafting - Healthy cartilage is taken from a donor site and implanted into the recipient sight 
- Causes problems in both the donor site and recipient sight including reduced mobility 
and excessive pain and bleeding at the donor sight. 
- As healthy tissue is damaged, the harms may outweigh the benefits of this treatment. 
 
Figure 3. Displays exemplary healthy tissue inclusive of bone and cartilage taken from donor site. 
 
 
1.2.1. Osteoarthritis and TGF-β1 
 
OA effects the entire joint structure (inclusive of the articular cartilage, subchondral bone and synovium tissue); in 
osteoarthritis, during the early stages, the cartilage surface is still intact but some minor fibrillations can be seen [10]. 
When this sign is present, chondrocytes react by proliferation, which causes cell clusters to be formed. The superficial 
zone also displays fibrillations leading to chondrocytes being lost. Slowly, the fibrillations transform into fissures 
extending into the mid zone, the cartilage begins to erode, the bone surface begins to wear and finally deformation 
occurs [11]. For osteoarthritis in particular, there are multiple factors including a higher rate of pro-inflammatory 
cytokines, examples including TNF and interleukin, chemokines and degradation enzymes (MMP’s, aggrecanases) 
which are suspected to effect progressive cartilage loss by activating an inflammatory signal leading to apoptosis [10]; 
TGF-β1 is thought to reduce the effects of these cytokines. 
 
Latest research on transgenic mice studies point out that TGF-β signalling pathways play a critical and unique role in 
chondrocytes during the development of osteoarthritis, and progress by driving chondrocytes toward hypertrophy, 
encouraging osteo-progenitor cell differentiation into osteoblasts alongside stimulating fibrosis [12]. It is a perceived 
fact that large amounts of TGF-β1 are present in healthy cartilage however in the samples of cartilage on which 
osteoarthritis has had its effect, TGF-β1 content is lower in quantity; this fact being supported by the research of 
renowned scientists worldwide [13-26]. In order to further support these findings, an experiment was carried out where 
naïve murine knee joints were injected with the TGF-β1. The effect of this action was an observed increase in 
proteoglycan content [4]. In addition, when the same experiment was carried out on a sample of rheumatoid arthritis 
 
 
cartilage samples, it was found that the growth factor had indeed ensured the cartilage was sheltered from extensive 
loss of proteoglycans [27]. 
 
1.2.2. The Role of TGF-β1 in Pathophysiology 
 
Towards the end of the 1980’s, TGF-β1 had shown many effects on cellular biology, whether it be simulation or 
inhibition of cell proliferation, alongside inflection of cell growth, differentiation, production of ECM, remodelling, 
and producing both hormones and growth factors. It was also discovered within this time that other major biological 
responses and diseases effected by the transforming growth factor included its effects on wound healing and fibrosis, 
inhibiting proliferation, promotion of chemotaxis, and regulation of apoptosis, differentiation and immune cell 
function [28]. 
 
Soon after looking into TGF-β1, it became evident that additional isoforms and other related growth factors had 
significant effects on the changes in human physiology. It was found that the TGF-β1 family could be distinguished 
from other growth factor groups via the identification of signalling; the TGF-β1 family signal through the 
transmembrane serine- threonine kinase receptors. Furthermore, the majority of cells may express this growth factor. 
The responses to this growth factor family may differ greatly depending on the manner in which the receptors are 
expressed at the surface of the cell, the proteins which are activated/regulated from the receptors, and the secondary 
pathways which are active within the relevant cell alongside the transcriptional complexes which are being made in 
the nucleus. Combined, the overall effect is that depending on the differing cells and contexts, various differing genes 
and signalling responses are either activated or repressed, responding to the signal expressed by the growth factor. 
 
Cytokines are proteins/peptides of glycoproteins that are secreted by cells and are involved in interaction and 
communication between cells. The regulation of proteoglycan metabolism has been affected by a variety of growth 
factors, one known as TGF-β1. This is an anabolic cytokine, which controls mainly cell differentiation and 
proliferation (rapid growth of cells) [7]. In terms of articular cartilage, TGF-β1 can be produced by osteoblasts and 
osteoclasts. It is said to have both pro and anti-inflammatory properties, which is why observing the presence of TGF- 
β1 on degraded cartilage is considered a topic of great interest. TGF-β1 has also been known to kill T cells, which 
attack our tissue, alongside promoting wound healing by simulating matrix protein synthesis and decreasing 
degradation. If the presence of TGF-β1 shows effect retaining components from the ECM or even possibly 
reproducing some of the damaged components, it could essentially provide a key light in curing degenerative diseases 
such as osteoarthritis. 
 
1.2.3. TGF-β1 and ECM 
 
TGF-β1 plays a critical part in cell attachment, migration, invasion, wound healing and fibrosis. This growth factor 
regulates the makeup of the ECM alongside the adhesive interactions between cells and the matrix in a large variety 
of cell type [28]. The ability derives from the unique control that TGF-β1 has though cell type specific regulation of 
protein expression within the matrix; it has been known to induce the expression of fibronectin, collagens and other 
glycoproteins [28]. 
 
Not only the growth factor simulate cells in order to make ECM proteins, but it also regulates the expression of 
proteins, which are involved in the degradation of these proteins by reducing the production of the enzymes, which 
are present during degradation, contradictory to its ability to induce the expression of various proteases. Although it 
seems to have conflicting effects depending on the context of the cell and nature of regulated protease expression, the 
overall effect is to inhibit the ECM from degrading [28]. By preventing degradation of the ECM, glycosaminoglycans 
(GAGs), a key hydrophilic element located within chondrocytes will not be lost; with osteoarthritis being a 
degenerative disease, the fact that TGF-β1 is rumored to prevent degradation, confirms that retention of GAGs is 
possible [28]. TGF-β1 also affects adhesion and interaction of cells with the matrix due to its additional ability to 
regulate adhesion receptors, which are known to cause mediation between cell interaction and ECM proteins [29]. 
 
 
1.2.4. TGF- β1 Signaling Pathways 
 
TGF-β1 works by signalling through a couple of receptors (TGF-β -RI (ALK5) and TGF-β -RII.) When the type 2 
receptor is bound to the growth factor, it can recruit and add the type I receptor to a phosphate group, thereby activating 
the SMAD receptors. The SMAD receptors respond to TGF-β signaling [30]. Normalisation of cell proliferation, 
differentiation and death occurs as an effect of SMAD (II, III, IV) proteins transducing signals from TGF-β 
superfamily ligands; activating the receptor serine/threonine kinases. SMADs 6 and 7 however may prevent TGF-β 
signaling due to their inhibitory nature [31]. 
 
Development of complexes with the mediating Co-SMAD (common mediating SMAD) occurs as an effect of 
phosphorylation of receptor-activated SMADs (R-SMADs) before they are moved to the nucleus for the TGF-β 
responsive genes are transcribed [31]. ALK’s are activing receptor like kinases, type I for TGF-β. The SMAD 1, 5 
and 8 pathways are used to signal the ALK 1, 2, 3 and 6. The SMAD 2 or 3 pathways are used to signal the ALK 4, 5 
and 7. With chondrocytes in particular, TGF-β is known to signal through ALK 1, thereby activating the SMAD 1, 5 
and 8 pathways during the differentiation stage [11]. 
 
A study was carried out in which it was predicted that interleukin intervention caused a lack of response to the TGF- 
β1 counteraction by down regulating SMAD 2 and 3 receptors alongside upregulating inhibitory SMAD receptors. 
[31]. Davidson et al found this research a topic of interest and further conducted a study on mice to observe PG 
synthesis after being exposed to anabolic cytokines and further induced with TGF-β1 [31]. It was found that less 
chondrocytes were present which expressed TGF-β1 receptors in the cartilage of mature mice. SMAD expression was 
unaffected, but then again SMAD2 phosphorylation was reduced with age. It can therefore be hypothesized from this 
research that the decreased TGF-β1 counteraction of IL-1 caused impairment to the chondrocytes present in the 
cartilage of mature mice because it had instigated a general reduction in TGF-β1 signalling capacity [31]. 
 
Joint diseases including osteoarthritis and rheumatoid arthritis may be effected by the presence of TGF-β1. They are 
both characterised by the decomposition of the AC, resulting loss of joint function. In osteoarthritic joints at the 
synovial tissue, excessive Proinflammatory cytokine IL-1 can be detected, alongside many forms of TGF-β1 and 
BMPs; the roles in that state are not clearly understood [28]. It is assumed that the presence of excessive TGF-β1 in 
patients suffering from rheumatoid arthritis is to protect the site from undergoing further damage via inhibition of 
macrophages and T cell proliferation. It has been proven that functional TGF-β1 signalling in overexpressed TGF-β1 
(in murine cells) protects lymphoid cells from development of rheumatoid arthritis alongside counteracting the 
destructing activity of the IL 1 by downregulating expression of the IL-1 receptor [28]. 
 
1.2.5. Problems Associated with Utilizing TGF-β1 
 
Adverse effects of administrating large amounts of TGF-β1 to a knee joint were found when adenoviral transfection 
was used to administer amounts of more than 20ng of TGF-β1. 20ng/ml is most definitely considered a satisfactory 
amount in order to continue collagen deposition, and when more than this amount is administered, the result ensures 
chondro-osteophyte formation [31]. The formation of osteophytes additionally narrows the space between the joint 
and bone leading to painful bone-to-bone contact and loss of function for the cartilage. In osteoarthritis, osteophytes 
mature in diarthrodial joints at the site of the joint capsule. The cells involved in the formation of osteophytes are 
present in the periosteum and the synovial lining within the capsule; osteophytes are formed from mesenchymal stem 
cells [32]. Osteophytes change the structure of the cartilage, weakening the resistance to compression of the joint. 
Many scientists have concluded that formation of osteocytes are indeed present and connected with cartilage that has 
been subjected to trauma [31-33]. The mesenchymal precursor cells derive the osteophytes during the differentiation 
process and it has been found in multiple studies that by inducing excessive amounts of TGF-β1, (more than 20ng/ml), 
osteophytes will more than likely be induced. 
 
Mesenchymal cells are stromal cells known to differentiate into other cell types; two main linages of mesenchymal 
differentiation include osteoblast and chondrocyte linages. The signalling of this specific growth factor with respect 
given to osteogenic and chondrogenic differentiation (which drives skeletal development) was studied. It was shown 
 
 
that BPM’s induce bone formation, promote mesenchymal cell commitment to osteogenic fate alongside inducing 
osteocyte apoptosis. TGF-β1 regulates each stage of chondrocyte, osteoblast and osteoclast differentiation [28]. TGF- 
β1 unfortunately cannot regulate commitment of mesenchymal stem cells to the osteoblast linage as it fails to convert 
c2c12 myoblast cells into osteoblast completely differentiated [28]. On the other hand, however, it does play a role in 
simulation of causing proliferation of osteoblast progenitors; acting as a chemoattractant for these cells, it becomes 
clear as to why these progenitors are present in high amounts at the fracture sites around which TGF -β1 has been 
released [28, 34, 35]. 
 
2. Applications of Photonics in Cartilage and Bone Treatment 
 
In addition to the broad applications of optics and photonics in optoelectronics devices [36-40], recently they have 
increasingly become applicable in biomedical applications such as surgery [41], sensing [42], photodynamic therapy 
[43-44], photothermal therapy [45-46] and nanoscale imaging [47]. Biomedical applications of photonics have broad 
aspects including laser, carbon nanotubes (CNTs), quantum dots (QDs), graphene and photodynamic therapy (PDT). 
 
2.1 Laser 
 
Laser, light amplification of by stimulated emission of radiation, plays a crucial role in biomedical and dental and 
orthopedic applications of photonics [48]. Laser technology has long traditional surgical applications for about 40 
years, few years after the invention of CO2 laser by C. Kumar N. Patel in 1964 [49-51]. Today different types of lasers 
such as CO2 (10,600 nm) [52], Nd:YAG (1,064 nm) [53], Er:YAG (2940 nm) [54,55] and Ar (514 nm) [56] lasers 
have become a promising tool in medical applications. Research achievements of short-pulsed infrared laser systems, 
during the late 1980s and 1990s, had opened up a new window for the laser applications in bone and dental hard 
substances [57]. The best bone ablation results are corresponded to the laser systems operating in wavelengths of 2.9, 
3, and 5.90-6.45 µm absorbed by biological hard tissue [58]. Following to this investigation, Er:YAG (2.94 µm), 
Er,Cr:YSGG (2.78 µm) and CO2 lasers seemed to be the most effective candidate for the purpose of cutting 
mineralised tissue [59-62] and hard-tissue ablation [63]. Generally reducing the operating time and complications of 
surgeries are benefited by laser application in surgery [64]. 
 
Laser Induced Breakdown Spectroscopy (LIBS) is another application of laser in medical applications and it enables 
real-time tissue identification for tissue specific ablation, for example differentiation between cartilage tissue and 
cortical bone tissue [65]. Specifically, in cartilage and bone tissue surgery, another concern is to provide enough 
information of what kind of tissue is being ablated at the bottom of the cut while laser is utilised in order to prevent 
iatrogenic damage of structures. As an example, in the temporomandibular joint (TMJ), the main goal of a surgery is 
specific ablation and shaping of diseased cartilage, bone or synovial tissue and also extensive removal of MTJ 
structures; while LIBS provides enough information via real-time tissue observation [65]. 
 
2.2 Carbon Nanotube (CNT) 
 
In addition to laser, CNT is another promising biomaterial candidate for the purpose of tissue regeneration in 
orthopedic [66], dental implants [67 and ex-vivo biosensing [68]. CNTs exists as multiwall or single wall 
metallic/semiconductor hollow cylinder with diameter of 0.2-7 nm; while the lengths are typically micrometers. 
Unique optical, mechanical, electrical and thermal properties of CNTs as well as their functionalisation capability and 
biocompatibility make them impressive capacity in biomedical applications such as scaffold for bone tissue 
engineering, dental implant and drug delivery systems [69-74]. In regard to the unique mechanical properties of CNTs, 
low fracture toughness and fragility of hydroxyapatite which has been largely used for maxillofacial surgery and 
orthopedic/dental implant can be compensated by adding single wall carbon nanotubes (SWCNTs) to the 
hydroxyapatite structure (HY-SWCNTs) and it will become more resistant with enhanced biocompatibility [75-78]. 
Furthermore, HY-SWCNTs could increase the bone formation as well as speed up the bone-healing process in 
diabetics suffered from a lower bone growth [79,80]. In orthopedic therapy, observation of the healing sites of the 
bone and detection of bone-related diseases are also challenging and important issues. Among other materials, CNTs 
 
 
bone sensors are promising candidates due to their excellent electrical and mechanical properties [81,82]; as bone 
regeneration accelerates under electrical conduction [83]. 
 
Another application of CNTs is to facilitate human bone marrow mesenchymal stem cell (MSC) chondrogenesis 
[84,85] due to its mechanical properties. Despite bone which has a self-repairing tissue, cartilage has a low 
regenerative capacity. Recent study demonstrated that MSC chondrogenesis is enhanced by electrospinning 3D 
biomimetic nanostructured scaffold based on hydrogen treated MWCNTs and biocompatible poly (L-lactic acid) 
(PLLA) polymer [84]. Importantly, this study showed that mechanical strength and a compressive Young’s modulus 
of scaffolds significantly increased and matched to natural articulate cartilage (∼0.75–2 MPa depending on location) 
[86-89] while the MWCNTs embedded scaffolds were utilised compared to a pure PLLA ones and it is due to the 
superlative mechanical properties of CNTs [84]. Notably, there is no an adverse effect on cellular activity was 
observed while there is a dramatic enhancement on mechanical strength [84]. 
 
2.3 Quantum Dots (QDs) 
 
In addition to CNTs, QDs, nanoscale semiconductor devices where electrons and holes are spatially confined in three 
dimensions, are also promising biomaterial candidates in biomedical applications [90-97] as well as optoelectronic 
applications [98-103]. From a physical point of view, semiconductor QDs exhibiting atomic-like discrete energy levels 
are of great interest in a wide range of applications from light-emitting diodes [99] and solar cells [101,102] to 
fluorescence tags for biomedical imaging [93-96] due to their unique optical and electrical properties and high 
quantum efficiency. QDs were first discovered by Alexey Ekimov in 1981 initially published in Russian language and 
then published in English in 1982 [104,105] and after less than two decades in 1998, their first biomedical applications 
as ultrasensitive biological detectors [106] and fluorescent biological labels were reported [107]. QDs nanoparticles 
are great candidates which allow real-time observation of bone regeneration and feature healing due to the unique 
optical properties and high quantum efficiency. Human bone marrow-derived mesenchymal stem cells (hMSCs) have 
exceptional bone regenerative potential, while QD attachment to hMSCs allow to monitor the cell regeneration under 
confocal microscope [108]. In this study, MC3T3-E1 osteoblast cells attached to the biocompatible hydroxyapatite 
(HA) were fluorescently labelled using hydrophilic CdSe/ZnS QDs as nanoparticles which allow direct observation 
of bone growth [108]. 
 
2.4 Photodynamic Treatment (PDT) 
 
PDT is another aspect of photonics applications in clinical treatments. In PDT, highly cytotoxic singlet oxygen (1O2) 
produced by light absorption of photosensitiser destroy the cancer cells or modify molecules and cell organelles which 
are close to the sites of formation of singlet oxygen [109-114]. The photosensitiser light absorption, the penetration 
depth of excitation light into tissue and the availability of tissue oxygen are main factors affected on PDT efficiency. 
The excitation light wavelength is also depending on the medical purpose of PDT; for example, a short wavelength 
excitation is applied in order to maximise the penetration depth while a long wavelength excitation is utilise to limit 
the penetration depth and to avoid exposing the deeper healthy tissue. In terms of the biological compatibility, 
maximum optical transparency and deep tissue penetration can be utilised by near-infrared (NIR) photosensitization 
enabling the remote treatment and also thick tumor [115]. In addition to the cancer treatment, PDT can also be utilised 
to activate the TGF-β1 which is one of the main bone growth factors thought the oxidative mechanism [116]. Disks 
of bovine articular cartilage were photosensitized by incubation with a chlorin-succinylated polylysine conjugate and 
irradiated with 1-2 J/cm2 red light (λmax = 671 nm). These two-steps regimen dramatically inhibited IL-1-stimulated 
proteoglycan degradation and concomitantly increased latent and active TGF-β1 in culture medium [116]. 
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